Genmab A/S (NASDAQ: GMAB) announced that worldwide net sales of DARZALEX (daratumumab) totaled $3.964 billion in the first quarter of 2026, according to data reported by Johnson & Johnson.

The sales figures include both intravenous and subcutaneous formulations of the cancer treatment. Net sales in the United States reached $2.208 billion, while international markets generated $1.756 billion in revenue.

Genmab receives royalties on the worldwide net sales of DARZALEX under an exclusive worldwide license agreement with Johnson & Johnson's Janssen Biotech subsidiary. The agreement covers development, manufacturing and commercialization of daratumumab.

The subcutaneous version is marketed as DARZALEX FASPRO in the United States and contains daratumumab and hyaluronidase-fihj. Johnson & Johnson handles global commercialization of both the intravenous and subcutaneous products.

Copenhagen-based Genmab is a biotechnology company focused on antibody medicines for cancer and other diseases. The company was established in 1999 and maintains operations across North America, Europe and Asia Pacific.